Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
Status:
Recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
This is a study to test how safe the combination of the drugs Romidepsin and Pralatrexate are
in patients with lymphoid malignancies and to determine the dose of the combination of drugs
that is safest. If the combination is determined to be safe, the study will continue accrual
patients with peripheral T-Cell lymphoma (PTCL).